May 2019 Volume 15, Issue 5

Volume 15, Issue 5 | May 2019
May 2019
In this Issue
Editor's Focus

Editor's focus: Vaccines increasingly under perilous scrutiny
Vaccines hardly deserve the suspicion they're being faced with of late, but developers need to keep their standards high and meet it nonethelessBusiness & Government Policy

A hefty price tag for NLRP3
Novartis snaps up subsidiary IFM Tre and trio of NLRP3 antagonist molecules
Wings Therapeutics launches
ProQR spins out all dystrophic epidermolysis bullosa activities
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
Eisai buys out Purdue rights
Move officially ends collaboration on sleep-wake regulation agent
Patent Docs: A Solution in Search of a Problem
Kevin Noonan discusses the Biologic Patent Transparency Act and how he thinks the U.S. Congress might be picking the wrong target (patents) as a way to decrease drug prices and increase transparencyDiscovery

Interest in inosine
ALS cells lose critical enzyme that protects neuronal cells
Machine learning vs. NASH
Gilead Sciences and insitro launch collaboration for AI-enabled drug discovery against NASH
Keep a good thing going
Expanded collaboration in Huntington’s disease research to explore stem cell and genetic therapeutics
Managing the microbiome
A roundup of a few recent news stories related to microbiome discoveries
A fifth collaboration for AI-driven firm
Ono and twoXAR announce neurological drug discovery dealResearch & Development

Disruptive double agent
Existing drug may successfully treat aggressive tumor
Through the ages
Two unique research paths emerge, looking at the fundamentals of aging and ancient origins of disease
Splice-Break finds key DNA deletions
A new approach to studying deletions in the mitochondria could inform disease study
A booster for immuno-oncology drugs
Australia’s Noxopharm unveils preclinical results on idronoxilFeature

At the forefront of cancer research
We look at FLIP, STING and other potentially groundbreaking areas of oncology therapeutics R&D
ISSCR Show Preview: Sunny days for stem cells
ISSCR makes its way to sunny L.A. for its 17th annual meetingClinical Trials

Bile acid modulation
Drug aids in reducing rare pediatric liver disease
Plenty of momentum for inarigivir
Spring Bank reports positive response from ACHIEVE trial, kicks off CATALYST trials
Guselkumab goes into development for FAP
MorphoSys announces that licensee Janssen has expanded clinical development of drug into familial adenomatous polyposis
Improving the experimental landscape
CRA and TLS’ VISITOR take different paths toward road to clinical trials, success of new drugsQ&A

Q&A: Concern as NAFLD and NASH rates rise
DDNews speaks with Mount Sinai researcher about the past, present and future of these liver conditionsContract Services

Modeling proteins better
Sygnature Discovery announces collaboration with software firm SilcsBio
A platform partnership
CrownBio and HUB ink license agreement to offer their PDX and organoid platforms together
Vetter’s Skokie facility expansion nears completion
Facility growth is necessary to help meet customer demands and new product requirementsDiagnostics

Real-world data vs. MS
Clinico-genomic collaboration propels multiple sclerosis research
Predicting obesity?
Researchers may be able to use genetic profiles to predict obesity risk at birth
Getting more eyes on glaucoma
Mannin Research, Biointerfaces Institute to pursue GDF15 biomarker diagnostic for eye disease
Homing in on PTSD
IU researchers discover potential test for post-traumatic stress disorderPreclinical

Triggering clean-up lessens inflammation
Inhibiting choline kinase leads to mitophagy, which could stave off inflammasome activation
Notable results for NYX-458
Data in Parkinson’s disease model demonstrate reversal of cognitive deficits with NYX-458
Advancing apace with ADAPTIR
Aptevo advances bispecific candidates, sees encouraging preclinical data
A gene therapy for wet AMD
Adverum presents first preclinical data on dosing contralateral eye with ADVM-022Commentary

Out of Order: Of mice and…well…other mice
Trying to present the news without too much fanfare (and with maximum accuracy) means resisting temptation, but it's effort well-spent
Guest Commentary: Moving beyond regulatory analytical requirements for better biotherapeutics
There are several analytical methods that must be developed for biotherapeutics; among the most important of these are host cell proteins

Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe